In the clinical setting and clinical trials, the PD‐L1 tumor proportion score (TPS) and tumor mutation burden (TMB) are adopted to predict the response to ICIs; however, these factors have been gradually proven not to be definitive biomarkers. This evidence concerns the gene CD274 and neoplasm.